Find the guidelines

• NICE: Ovarian Cancer Pathway Overview
• NICE: Ovarian Cancer Quality Standard (QS18 / May 2012, re-checked by NICE November 2017)
• NICE: Ovarian Cancer Recognition and Early Management (CG122 / April 2011, re-checked by NICE November 2017)
• Macmillan Rapid Referral (endorsed by NICE) ( p23 / Jan 2016)

Recent NICE features:

Once a day pill for ovarian cancer could be made available on the CDF (Feb 2018)

Tests in secondary care to identify people at high risk of ovarian cancer (Nov 2017)

Image via targetovariancancer.org.uk

Behind the headlines

“Vitamin D may reduce the risk of some cancers”  – Thursday March 8 2018

The study adds some evidence in favour of the theory that vitamin D may protect against cancer, in addition to its known role in helping the body absorb calcium and keeping bones strong. Previous studies have been inconsistent, with no clear results. But this study’s findings aren’t conclusive. It has a number of limitations. check out the full article here 

“Paternal genes may influence ovarian cancer risk” – Friday February 16 2018

This is valuable research that explores the possibility of there being an additional ovarian cancer risk gene positioned on the X chromosome. This could possibly explain the inheritance of any cases of cancer seen in a woman (and any sisters) and just her paternal grandmother. It’s not a new finding that fathers can pass cancer genes on to their daughters, but the possibility that the researchers have found another ovarian cancer risk gene positioned on the X chromosome is novel and significant. There are still many questions that can’t be answered at the moment. This database also mostly included only people of white ethnicity, and hereditary risk could differ in other ethnic groups. check out the full article here

healthtalk.org can help you and your patients understand what it is like to have a health condition, by hearing about the experience from patients who’ve been through the same.

Supporting your learning

No time to read Cochrane Reviews? Think again!

Cochrane Clinical Answers covers 32 Clinical Specialties and provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane systematic reviews. They are designed to be actionable and to inform decision making at the point of care. Each Cochrane Clinical Answer contains a clinical question, a short answer, and an opportunity to ‘drill down’ to the evidence from the Cochrane Review. The target audience for Cochrane Clinical Answers is healthcare practitioners and professionals.

http://cochraneclinicalanswers.com/

Some examples of questions to Cochrane Clinical Answers:

What is the risk of ovarian cancer in subfertile women treated with ovarian-stimulating drugs?

In women with early stage epithelial ovarian cancer, is there randomized controlled trial evidence to support the use of adjuvant chemotherapy?

What are the effects of pre-operative chemotherapy in women undergoing surgery for advanced ovarian epithelial cancer?

What are the benefits and harms of PARP inhibitors in women with ovarian cancer?

Recently published by Christie Staff

Preclinical assessment of CAR T-cell therapy targeting the tumor antigen 5T4 in ovarian cancer.

Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management.

929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers.

More articles available to view at The Christie Repository